Key Takeaways
- “Herbal,” “traditional,” “food” and “supplement” do not mean pharmacologically inactive. A product can alter drug concentration, add to a drug’s effects or cause toxicity of its own.
- The exact product matters. Common names can refer to different species; extracts have different concentrations; multi-ingredient formulas and batches may not be equivalent.
- Bring the container or clear photographs, not only a translated herb name. Record ingredients, manufacturer, strength, dose, frequency, reason, start date and last dose.
- Interactions deserve the most urgent review when medicines have a narrow therapeutic range or protect a transplant, prevent clots or seizures, treat cancer/HIV, control rhythm or cause sedation.
- Do not use a universal online “stop all herbs for two weeks” rule. Surgery, pregnancy, liver or kidney disease and cancer treatment require product-specific advice and a written stop/restart decision.
- Absence from an interaction checker does not prove safety. For many herb–drug pairs, evidence is limited, products vary and the relevant ingredient may be unclear [1][2].
Content
A patient may carefully report every prescription yet omit the tea taken for sleep, the concentrated extract bought online, the traditional formula prescribed elsewhere and the powder mixed into breakfast. The omission is rarely deliberate. Many people do not think of these products as “medicines.” Pharmacologically, however, the body does not sort swallowed substances by the shop aisle where they were purchased.
The useful conversation is not “Are herbs good or bad?” It is: what exactly is the product, what exposure does it create, what medicine or condition could it affect, and what decision needs to be made now?
First identify what kind of product is actually being used
Across countries, the same-looking capsule may be regulated as a prescription traditional medicine, an over-the-counter medicine, a health food, a dietary supplement or an ordinary food. Those categories have different standards and do not travel with the product across borders.
In the United States, FDA does not approve dietary supplements for safety and effectiveness before they are sold; companies are responsible for safety and compliant labelling, while much regulatory action occurs after marketing [3]. In China, health-food labels must state that the product cannot replace medicine and may not claim disease prevention or treatment [4]. Neither fact says that every product is unsafe. Both facts mean that the word “supplement” is not evidence of drug-like premarket review or suitability for a particular patient.
Do not collapse these distinct items into “Chinese herbs” or “vitamins”:
- a prescribed multi-herb formula or decoction pieces;
- a standardized single-plant extract;
- a vitamin or mineral at nutritional or high dose;
- concentrated tea extract versus a beverage consumed as food;
- tinctures, powders, gummies, oils and topical products;
- probiotics, mushrooms, bee products or animal-derived traditional products;
- products marketed for weight loss, sexual performance, bodybuilding, sleep or “detox.”
Products promoted in the last group deserve particular scrutiny because undeclared pharmaceutical ingredients and contamination have been documented in some supplement markets [5].
A usable list identifies the bottle, not just the plant
For every non-prescription product, capture:
- exact name in the original language and any translated name;
- all listed ingredients and amount per unit or serving;
- botanical Latin name and plant part, if stated;
- extract ratio or standardization, if stated;
- manufacturer, country, registration/record number and batch/lot;
- tablet, capsule, tea, granule, decoction, tincture, oil or topical form;
- actual dose and frequency—not merely the label suggestion;
- reason for use, start date and last dose;
- who recommended it and where it was obtained;
- any symptom, laboratory change or benefit noticed after starting.
Photograph every side of the package in good light, including the ingredient panel and batch. For a clinic-dispensed formula, request the prescription with each component and dose. If a bag has no label, say that openly; do not guess its identity from colour or smell.
A translated common name is not enough. “Ginseng,” for example, can refer to different Panax species or to products that are not botanically ginseng. A cup of brewed tea and a concentrated extract cannot be assumed to create the same exposure.
Interactions happen through more than one pathway
Clinicians and pharmacists look for at least five kinds of problem.
Changed drug concentration. A herb may induce or inhibit metabolic enzymes or transporters, changing absorption, breakdown or clearance. St John’s wort induces cytochrome P450 enzymes and intestinal P-glycoprotein; clinically significant interactions have been documented with cyclosporine, warfarin, oral contraceptives, digoxin, some HIV medicines and some cancer medicines [2][6]. The danger may be treatment failure rather than an obvious side effect.
Added pharmacological effects. Multiple products may push in the same direction: more sedation, bleeding tendency, low glucose, low blood pressure, stimulation or serotonin activity. The strength of evidence differs by product. A theoretical concern or case report should not be presented as equal to a controlled clinical interaction.
Organ toxicity. A product can injure liver or kidney independently, then make a prescribed medicine harder to tolerate or clear. “No interaction found” does not exclude direct toxicity.
Laboratory interference. Biotin and other supplements can distort some laboratory assays. A result that does not fit the clinical picture should prompt review of supplements, timing and assay method before a major decision.
Product mismatch. The label may be incomplete, the wrong species may have been substituted, or the concentration may vary. NCCIH notes that some commercial goldenseal supplements contained little goldenseal and undeclared ingredients; goldenseal also inhibits important metabolic enzymes and has reduced metformin exposure in a human study [2][7].
Evidence should be graded, not turned into a viral “never combine” list
An interaction assessment should state what supports it:
- human pharmacokinetic or clinical outcome data;
- a product label or formal regulatory warning;
- repeated case reports with plausible timing;
- laboratory or animal evidence only;
- theoretical overlap without clinical confirmation;
- no usable evidence, which means uncertainty—not proven absence.
This distinction matters. NCCIH reports documented high interaction risk for St John’s wort, but mixed or inconclusive evidence for some proposed Asian ginseng interactions [2]. Telling a patient that every ginseng product “will cause bleeding” overstates the evidence. Saying that the exact product and concurrent anticoagulant need review is more accurate and safer.
Likewise, “I have taken it for years without a problem” cannot exclude an interaction after a new cancer medicine, anticoagulant or anaesthetic is added. Conversely, an interaction database flag does not automatically require stopping a beneficial prescribed traditional medicine; the team must assess product, dose, evidence and clinical alternatives.
Prioritize the combinations where a small change matters most
Same-day pharmacist or prescriber review is sensible when a patient uses herbs or concentrated supplements with:
- warfarin, direct oral anticoagulants, antiplatelet medicines or perioperative anticoagulation;
- tacrolimus, cyclosporine or other transplant immunosuppression;
- oral anticancer treatment, chemotherapy or targeted therapy;
- antiretroviral medicines;
- antiseizure medicines;
- digoxin, antiarrhythmics or medicines that prolong cardiac repolarization;
- lithium, antidepressants or multiple serotonergic medicines;
- insulin or sulfonylureas;
- benzodiazepines, opioids, sleeping tablets or other sedatives;
- medicines with a narrow therapeutic index.
NCCIH specifically highlights narrow-therapeutic-index drugs such as digoxin, cyclosporine and warfarin because a modest concentration change can have major consequences [8]. Do not wait for the next routine appointment if there is unexpected bleeding, thrombosis, transplant dysfunction, seizure, severe hypoglycaemia, arrhythmia, confusion or loss of treatment effect.
Cancer treatment needs the actual regimen and treatment date
“Safe during chemotherapy” is not a meaningful universal label. Different anticancer drugs use different enzymes and transporters, and treatment may also include immunotherapy, radiotherapy, surgery or hormonal therapy. NCI notes that supplements and herbs can alter absorption, metabolism or excretion of anticancer medicines, while evidence for many combinations remains limited [9].
Give the oncology pharmacist:
- cancer diagnosis and current treatment intent;
- generic names and cycle dates for every anticancer medicine;
- radiation field or planned operation when relevant;
- the full supplement product record;
- liver, kidney and blood-count abnormalities;
- the decision requested: continue, pause, monitor, substitute or avoid.
Antioxidant claims require the same discipline. Laboratory rationale is not proof of clinical benefit, and “supports immunity” is not an adequate reason to combine a product with immunotherapy. NCI states that no diet, vitamin, mineral or herbal supplement has been proven to cure cancer or prevent its return [10].
Surgery requires a product-specific stop and restart plan
Some supplements may affect bleeding, blood pressure, heart rate, sedation, glucose or the response to anaesthesia. NCCIH advises telling the surgical team well in advance because supplements can affect bleeding or anaesthetic response [11].
Do not independently apply a fixed stop interval to every product. Ask the surgeon, anaesthesiologist and pharmacist to document:
- product and last dose;
- reason for stopping or continuing;
- exact stop date;
- monitoring or replacement needed;
- who decides when to restart after surgery.
Stopping may also have consequences. A product used regularly for mood or sleep should not be withdrawn casually without knowing its ingredients and the patient’s other medicines. For emergency surgery, disclose the last dose; do not hide use because it was not stopped in time.
Never make an interaction safer by quietly changing the prescription drug
If a potential interaction is found, patients should not halve an anticoagulant, skip transplant medicine, stop antiseizure therapy or change cancer treatment themselves. The harm from losing essential treatment may be immediate.
The clinical options include:
- stop or replace the nonessential herbal product;
- change timing only when separation can plausibly prevent the interaction;
- choose a different prescribed medicine;
- adjust dose using validated drug-level or clinical monitoring;
- continue with defined warning signs and follow-up;
- defer a procedure or treatment until exposure has cleared.
Taking the herb “four hours apart” helps only for certain absorption interactions; it does not prevent enzyme induction, organ toxicity or additive bleeding and sedation.
Cross-border reconciliation should preserve uncertainty
Translate the ingredient list, but keep photographs of the original label. The receiving clinician may know a botanical by its Latin name but not a regional brand; the home clinician may recognize the original formula but not its English transliteration.
The handover should distinguish:
- confirmed ingredient and dose;
- patient-reported ingredient with no label;
- formula whose components are known but concentration is not;
- suspected interaction and the strength of evidence;
- last dose and any observed effect;
- agreed stop/restart decision and responsible clinician.
Do not convert “unknown” into “safe” during translation. An incomplete product is a reason for more caution, not a blank line on the medication list.
FAQ
1. Do I need to report teas and powders that are just foods?
Report products used regularly for a health effect, especially concentrated extracts, medicinal teas and multi-ingredient powders. Ordinary occasional foods may also matter when a medicine has a known food interaction. Let the pharmacist decide relevance from the actual product and amount.
2. Can I check interactions using only the herb’s English name?
No. Record the original name, botanical name if available, plant part, extract, manufacturer and all ingredients. Common names and translations can map to different species or formulas.
3. Should every herbal product be stopped two weeks before surgery?
Not by self-direction. Tell the team early and obtain an exact stop and restart plan. Risks and clearance differ, and suddenly stopping a regularly used product may also need management [11].
4. If an interaction checker shows nothing, is the combination safe?
Not necessarily. Evidence is missing for many pairs, and the database may not identify a regional multi-herb product or variable extract. Absence of a listing should be documented as uncertainty, not proof of safety [1][8].
5. Which medicines make herb interactions especially urgent?
Transplant drugs, anticoagulants, cancer and HIV therapies, antiseizure drugs, digoxin/antiarrhythmics, diabetes medicines and sedatives deserve prompt review. These treatments can have serious consequences if exposure becomes too low or too high.
Sources
- National Center for Complementary and Integrative Health — How Medications and Supplements Can Interact
- National Center for Complementary and Integrative Health — Herb–Drug Interactions: What the Science Says
- U.S. Food and Drug Administration — FDA 101: Dietary Supplements
- State Administration for Market Regulation — Requirements for Health-Food Labels and Instructions
- National Center for Complementary and Integrative Health — Safe Use of Complementary Health Products and Practices
- National Center for Complementary and Integrative Health — St John’s Wort: Usefulness and Safety
- National Center for Complementary and Integrative Health — Goldenseal: Usefulness and Safety
- National Center for Complementary and Integrative Health — Six Tips on Herbs and Medicines
- U.S. National Cancer Institute — Cancer Therapy Interactions With Foods and Dietary Supplements
- U.S. National Cancer Institute — Popular Diets, Supplements and Cancer
- National Center for Complementary and Integrative Health — Using Dietary Supplements Wisely